Coherence Neuro raises $45 million for a brain-tumor implant
Founders Fund and the OpenAI Startup Fund co-led the Series A, which will fund a first long-term human trial in glioblastoma.
Coherence Neuro announced a $45 million Series A on October 21, co-led by Founders Fund and the OpenAI Startup Fund. Lux Capital, 8VC and others joined, along with earlier backers. The company builds implants that record and stimulate brain-tumor tissue. It says the money will pay for a first long-term human trial in glioblastoma, an application for FDA Breakthrough Device designation, and preclinical work in pancreatic cancer. The round follows a $10 million seed in 2025.
So far, the company’s evidence comes from mouse studies and a short study during surgery at Royal Melbourne Hospital. No results from that study have been published, and no patient has yet received a long-term implant.
Learn more: Coherence Neuro’s first human study · Closed-loop systems